Exelixis, Teva reach settlement on Cabometyx patent dispute

24 Jul 2023
endpts.com
Patent Infringement
Exelixis has settled a patent dispute over Teva’s attempt to market a generic version of its blockbuster cancer drug Cabometyx, pushing generic competition into the next decade.
The settlement resolves a case brought by Exelixis in Delaware federal court over a patent that expires in 2032 and covers processes to make compounds containing quinolines, a type of organic compound. As part of the deal, Exelixis has agreed to give Teva a license to market its generic version on Jan. 1, 2031, pending FDA approval, Exelixis announced Sunday.
Exelixis, Teva reach settlement on Cabometyx patent dispute
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.